Approaches to Estimating Clearance Rates for Human Papillomavirus Groupings: A Systematic Review and Real Data Examples

Wijstma, ES (通讯作者),Nieuwe Achtergracht 100, NL-1018 WT Amsterdam, Netherlands.
2023-1
Introduction:Approaches to estimating clearance rates, an important metric of human papillomavirus (HPV) clearance, for HPV groupings differ between studies. We aimed to identify the approaches used in the literature for estimating grouped HPV clearance rates. We investigated whether these approaches resulted in different estimations, using data from existing studies. Methods:In this systematic review, we included articles that reported clearance rates of HPV groupings. We identified approaches to data in the HAVANA cohort, comprising adolescent girls, and the H2M cohort, comprising men who have sex with men. We estimated clearance rates for six HPV groupings (bivalent-, quadrivalent- and nonavalent vaccine-related, and low-risk, high-risk, and any HPV). Results:From 26 articles, we identified 54 theoretically possible approaches to estimating clearance rates. These approaches varied regarding definitions of clearance events and person-time, and prevalence or incidence of infections included in the analysis. Applying the nine most-used approaches to the HAVANA (n = 1,394) and H2M (n = 745) cohorts demonstrated strong variation in clearance rate estimates depending on the approach used. For example, for grouped high-risk HPV in the H2M cohort, clearance rates ranged from 52.4 to 120.0 clearances/1000 person-months. Clearance rates also varied in the HAVANA cohort, but differences were less pronounced, ranging from 24.1 to 57.7 clearances/1000 person-months. Conclusions:Varied approaches from the literature for estimating clearance rates of HPV groupings yielded different clearance rate estimates in our data examples. Estimates also varied between study populations. We advise clear reporting of methodology and urge caution in comparing clearance rates between studies.
EPIDEMIOLOGY
卷号:34|期号:1|页码:119-130
ISSN:1044-3983|收录类别:SCIE
语种
英语
来源机构
Public Health Service Amsterdam; World Health Organization; International Agency for Research on Cancer (IARC); Netherlands National Institute for Public Health & the Environment; University of Amsterdam
资助信息
M.F. Schim van der Loeff received research funding from Sanofi Pasteur MSD; he was a co-investigator in a Merck-funded investigator-initiated study on Gardasil; he was an investigator on a Sanofi Pasteur MSD sponsored HPV vaccine trial; he served on advisory boards of GSK and Merck; he received in-kind contribution for another study from Stichting Pathologie Onderzoek en Ontwikkeling (SPOO); his institution received research funding from Janssen Infectious Diseases and Vaccines. The other authors report no conflicts of interest. The authors are solely respon-sible for final content and interpretation.
被引频次(WOS)
0
被引频次(其他)
0
180天使用计数
2
2013以来使用计数
2
EISSN
1531-5487
出版年
2023-1
DOI
10.1097/EDE.0000000000001550
WOS学科分类
Public, Environmental & Occupational Health
学科领域
循证公共卫生
关键词
human papillomavirus HPV clearance rate systematic review methodology
资助机构
Sanofi Pasteur MSD Merck(Merck & Company) MSD Janssen Infectious Diseases and Vaccines